The House Energy & Commerce (E&C) Health Subcommittee convened a legislative hearing to examine 18 bills aimed at improving patient access to treatments for rare diseases (hearing memo) – including legislation affecting the drug approval process at the Food and Drug Administration, Medicare and Medicaid coverage, and other issues. All bills are bipartisan, except for the Antimicrobial Resistance Research Assessment… (Eisen, March 1, 2024) #Costs, #Drug Pricing, #Food and Drug Administration, #Pediatrics, #Quality, #Value-Based Insurance Design, #Value-Based Purchasing